AC IMMUNE PARTNER GENENTECH TO START SECOND PHASE 3 CLINICAL TRIAL FOR ALZHEIMER'S THERAPY CRENEZUMAB
February 28, 2017 02:01 ET
|
AC Immune SA
Strong commitment to potential disease-modifying therapy New Phase 3 CREAD2 trial to investigate 750 participants Current Phase 3 CREAD1 trial of 750 participants expected to read out 2020 ...
AC IMMUNE PARTNER GENENTECH PRESENTS IMPORTANT DATA ON ALZHEIMER'S THERAPY CRENEZUMAB
December 09, 2016 15:49 ET
|
AC Immune SA
AC IMMUNE PARTNER GENENTECH PRESENTS IMPORTANT DATA ON ALZHEIMER'S THERAPY CRENEZUMAB Crenezumab higher dose in CREAD Phase 3 Alzheimer's trial supported by exposure-response model Phase 1b...
AC IMMUNE APPOINTS EXPERIENCED LIFE SCIENCE PROFESSIONAL AS NEW CHIEF FINANCIAL OFFICER
November 23, 2016 09:32 ET
|
AC Immune SA
Lausanne, Switzerland, November 23, 2016 - AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical stage biopharmaceutical company focused on neurodegenerative diseases, today...
AC Immune SA announces results of annual general meeting
November 15, 2016 07:06 ET
|
AC Immune SA
AC Immune Announces Results of Annual General Meeting Financial expert Mr. Thomas Graney elected as new member of the Board of Directors Shareholders approve all proposed resolutions of the...
AC Immune Reports Third Quarter 2016 Results
November 11, 2016 07:12 ET
|
AC Immune SA
LAUSANNE, Switzerland, Nov. 11, 2016 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ:ACIU), a Swiss-based, clinical stage biopharmaceutical company focused on neurodegenerative diseases, today announced...
AC Immune SA Reports Third Quarter 2016 Results
November 11, 2016 06:35 ET
|
AC Immune SA
AC Immune Reports Third Quarter 2016 Results Successfully Completed Initial Public Offering on NASDAQ, Net Proceeds of $ 70.5 million (CHF 69.4 million)* Lausanne, Switzerland,...
Switzerland's AC Immune Opens For Trading On NASDAQ
September 23, 2016 01:42 ET
|
AC Immune SA
SWITZERLAND'S AC IMMUNE OPENS FOR TRADING ON NASDAQ
LAUSANNE, Switzerland, Sept. 23, 2016 (GLOBE NEWSWIRE) -- AC Immune SA, a Swiss-based, clinical stage biopharmaceutical company focused on...
Switzerland's AC Immune Opens For Trading On NASDAQ
September 23, 2016 01:38 ET
|
AC Immune SA
SWITZERLAND'S AC IMMUNE OPENS FOR TRADING ON NASDAQ Lausanne, Switzerland, September 23, 2016 - AC Immune SA, a Swiss-based, clinical stage biopharmaceutical company focused on neurodegenerative...
AC Immune SA Announces Pricing of Upsized Initial Public Offering
September 22, 2016 18:21 ET
|
AC Immune SA
AC Immune Announces Pricing of Upsized Initial Public Offering Lausanne, Switzerland - September 23, 2016 - AC Immune SA announced today the pricing of its initial public offering of 6,000,000 of...
AC Immune SA Commences Proposed Initial Public Offering of Common Shares
September 13, 2016 16:53 ET
|
AC Immune SA
LAUSANNE, Switzerland, Sept. 13, 2016 (GLOBE NEWSWIRE) -- AC Immune SA announced today that it has commenced the initial public offering of 4,545,456 of its common shares pursuant to a registration...